Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608959 · ClinicalTrials.gov registry record · Phase 3
Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects
A Phase 3 study of Infection, sponsored by Cadence Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00608959: Completed Phase 3 study of Infection, sponsored by Cadence Pharmaceuticals.
NCT00608959 is a Phase 3 study of Infection that has completed, run by Cadence Pharmaceuticals. The registered enrollment target is 30 participants, below the 726-participant average among 41 other Infection trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608959, a Phase 3 study of Infection, has completed, sponsored by Cadence Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if omiganan 1% gel (the investigational medication in this research study) is effective and safe when compared to chlorhexidine 2% (an FDA approved medication) for killing bacteria (germs) that live on the surface of the skin. Both of the study medications are applied topically (on the surface of the skin).
Primary Outcome
Change in the mean number of skin bacterial counts (CFU/cm2) which was calculated by subtracting log10 CFU/cm2 at 72 hours (single sample per subject per timepoint) from the log10 CFU/cm2 at 0 hours (baseline) in Part 2.Baseline was calculated by 'pooling' samples from 6 sites adjacent to each timepoint.
Conditions Studied
Interventions
- DRUG omiganan 1% gel
- DRUG chlorhexidine 2% solution
Study Locations (1)
Montana
- BioSciences Lab - Bozeman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00608959 record still lists
NCT00608959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 726-participant average among 41 other Infection trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Infection appearing as the primary indexed condition, and to 2 interventions - of which omiganan 1% gel is the first listed.
NCT00608959 reports a single indexed study location in Montana.
Frequently Asked Questions
What is clinical trial NCT00608959 about?
NCT00608959 is a clinical study titled "Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects". The purpose of this research study is to determine if omiganan 1% gel (the investigational medication in this research study) is effective and safe when compared to chlorhexidine 2% (an FDA approved medication) for killing bacteria (germs) that live on the surface of the skin. Both of the study medi...
What is the current status of trial NCT00608959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2008-05. Estimated completion is 2008-06.
What conditions does trial NCT00608959 study?
This clinical trial studies the following conditions: Infection.
What interventions are being tested in trial NCT00608959?
The interventions under investigation include: omiganan 1% gel (DRUG), chlorhexidine 2% solution (DRUG).
Who is sponsoring clinical trial NCT00608959?
This trial is sponsored by Cadence Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00608959 being conducted?
This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00608959's enrollment target sits among peer trials
30 33rd of 41 higher than 8 of 41 other Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
COMPLETED · Phase 3
-
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
COMPLETED · Phase 3
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
Persona Revision Knee System Outcomes
RECRUITING
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia